
Opinion|Videos|August 14, 2024
Engaging mFARS Scale to Monitor Friedreich Ataxia Progression
An expert in Friedreich's ataxia evaluates the mFARS (modified Friedreich's Ataxia Rating Scale) measurement tool, highlighting its advantages and limitations, while also exploring alternative assessment methods for tracking disease progression.
Advertisement
Episodes in this series

- The mFARS measurement tool is frequently reserved for clinical trials due to its time-consuming nature. What alternative tool do you employ to monitor disease progression, and have you observed any shifts in these metrics following the approval of omaveloxolone?
- What is the clinical value of omaveloxolone in patients with wheelchair dependence?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
CAR T-Cell Therapies, Bispecific Antibodies Usher in New Era in R/R MCL
2
Emerging Breakthroughs in Neurodegenerative Disease Treatments: Kavita Nair, PhD, FAAN
3
Ibrutinib-Based Frontline Regimens Narrow the Survival Gap in CLL
4
Global CKD Burden Nearly Doubles Since 1990, Reaching 788 Million Adults Worldwide
5















































